The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II)

Publication date

2024-11-01

Authors

Parenti, Giancarlo
Fecarotta, Simona
Alagia, Marianna
Attaianese, Federica
Verde, Alessandra
Tarallo, Antonietta
Gragnaniello, Vincenza
Ziagaki, Athanasia
Guimaraes, Maria Jose’
Aguiar, Patricio

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by

Abstract

Clinical pathway recommendations (CPR) are based on existing guidelines and deliver a short overview on how to deal with a specific diagnosis, resulting therapy and follow-up. In this paper we propose a methodology for developing CPRs for Pompe disease, a metabolic myopathy caused by deficiency of lysosomal acid alpha-glucosidase. The CPR document was developed within the activities of the MetabERN, a non-profit European Reference Network for Metabolic Diseases established by the European Union. A working group was selected among members of the MetabERN lysosomal storage disease subnetwork, with specific expertise in the care of Pompe disease, and patient support group representatives. The working strategy was based on a systematic literature search to develop a database, followed by quality assessment of the studies selected from the literature, and by the development of the CPR document according to a matrix provided by MetabERN. Quality assessment of the literature and collection of citations was conducted according to the AGREE II criteria and Grading of Recommendations, Assessment, Development and Evaluation methodology. General aspects were addressed in the document, including pathophysiology, genetics, frequency, classification, manifestations and clinical approach, laboratory diagnosis and multidisciplinary evaluation, therapy and supportive measures, follow-up, monitoring, and pregnancy. The CPR document that was developed was intended to be a concise and easy-to-use tool for standardization of care for patients among the healthcare providers that are members of the network or are involved in the care for Pompe disease patients.

Keywords

Acid alpha-glucosidase deficiency, Acid maltase deficiency, Glycogen storage disease (GSD) type II, Lysosomal storage disease, Pompe disease, Genetics(clinical), Pharmacology (medical)

Citation

Parenti, G, Fecarotta, S, Alagia, M, Attaianese, F, Verde, A, Tarallo, A, Gragnaniello, V, Ziagaki, A, Guimaraes, M J, Aguiar, P, Hahn, A, Azevedo, O, Donati, M A, Kiec-Wilk, B, Scarpa, M, van der Beek, N A M E, Del Toro Riera, M, Germain, D P, Huidekoper, H, van den Hout, J M P, van der Ploeg, A T, Zeman, J, Witters, P, Weinhold, N, Vijay, S, van Hasselt, P M, Ullrich, K, Tournev, I, Salviati, A, Rutsch, F, Roland, D, Rokicki, D, Rodrigues, E, Pfliegler, G, Miclea, D, Martins, E, Martín-Hernández, E, Komninaka, V, Kingma, S, Jones, S, Hiwot, T G, Hennermann, J, Guffon-Fouilhoux, N, Grosso, S, López, A G M, Gasperini, S, Gaspar, A M, Ferreira, A, Eyskens, F, Dobbelaere, D & and the MetabERN Subnetwork for Lysosomal Disorders 2024, 'The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II)', Orphanet Journal of Rare Diseases, vol. 19, no. 1, 408. https://doi.org/10.1186/s13023-024-03373-w